Business Wire

CLUE

17.11.2021 01:03:12 CET | Business Wire | Press release

Share
Clue, a SaaS Investigation and Intelligence Platform, Announces £5m Strategic Growth Investment From Frog Capital

Clue, a SaaS platform for managing investigations, today announced growth investment of £5 million from Frog Capital, a leading investor in European scale-up software. Demand for Clue has more than doubled over the last two years, driven by co-owners Clare Elford, CEO, and Thomas Drohan, CCO. From its roots in policing, the platform is now used across government, private and non-profit sectors to investigate cyber-crime, fraud, child protection, corruption, environmental crime, cheating in sports and much more. Clare and Thomas are joined on the board of directors by Nick Harber, CFO; Mike Reid, Senior Partner at Frog Capital; and Adam Hale, Chair of the ScaleUp Institute, as Chairman.

Clare Elford, CEO, said: “The world of intelligence and investigations is no longer constrained to policing, there is much wider application. Organisations are under growing scrutiny, finding themselves more susceptible to threats and with a much greater duty of care towards the vulnerable.

“Clue has productised decades of investigation expertise into a platform that empowers intelligence officers and investigation experts to achieve successful outcomes. So many of those dedicated to preventing harm and seeking justice have to deal with an overwhelming volume and complexity of data. Still reliant on legacy systems, or even spreadsheets, this is a sector primed for digital transformation.”

Thomas Drohan, CCO, said “With this investment, we will strengthen the capabilities of the platform with further AI and ML capability, automation, data insights and business intelligence, while continuing to support and build our user community. Frog have a formidable track record, with an impressive team who we are looking forward to working with to deploy the Scale-up Methodology and drive business growth and a solution to better serve the market.”

Mike Reid, at Frog Capital who joins Clue’s board said: “Across the industries that Clue serves there's a deep-rooted frustration at the lack of good enough tech to allow people to do their investigative work as efficiently and thoroughly as they need. For too long there's been a staggering underinvestment in how investigations are done, resulting in missed opportunities and slow outcomes for hardworking investigative teams and the people they serve.

“Clue's technology is genuinely delivering very significant clients a step change in how they manage and resolve incredibly complex and sensitive investigation cases. With Frog’s investment and experienced team of operators, Clue can accelerate their incredibly positive organisational and, critically, social impact in the key fields of policing, child welfare, financial crime amongst many others.”

Clue’s new Chairman, Adam Hale, said: “'I first met Clare and Thomas just before the pandemic and was really impressed with what they had built and the magnitude of customer problem that Clue solves. Since then, working with the ScaleUp Group, they have raised value-added SaaS growth investment from Frog Capital. I have known Frog for many years and am delighted to become part of their portfolio. I'm also really excited to work with Nick Harber again. I studied Computer Science in Bristol in the 80s and love coming back to a city set to support high growth organisations such as Clue.

“Now is the 'end of the beginning' for Clue and the start of the path to market leadership. From speaking to customers, I can hear how invaluable Clue is to them. There is so much opportunity and I'm thrilled to be part of it.”

About Clue
Clue is a cloud-based investigation case management and intelligence platform that enables organisations to prevent harm and secure justice by building intelligence and quickly progressing investigations in the face of evolving threats, increasing volumes of data, and the need for multi-agency collaboration.

About Frog Capital
Frog Capital is a specialist software Scale-Up Investor in high-growth European software companies and software-enabled businesses at the Scale-Up stage. Frog has a team of in-house operating partners who actively support their portfolio at executive level across the wide range of business challenges they face. Frog has combined over 20 years of experience to create its unique Scale-Up Methodology, which provides a framework defining the major elements of success through the Scale-Up phase.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye